Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Liabilities (2017 - 2026)

Dr Reddys Laboratories has reported Total Liabilities over the past 10 years, most recently at $2.2 billion for Q1 2026.

  • For Q1 2026, Total Liabilities rose 20.91% year-over-year to $2.2 billion; the TTM value through Mar 2026 reached $2.2 billion, up 20.91%, while the annual FY2026 figure was $2.2 billion, 19.22% up from the prior year.
  • Total Liabilities for Q1 2026 was $2.2 billion at Dr Reddys Laboratories, up from $1.8 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $2.2 billion in Q1 2026 and troughed at $1.1 billion in Q1 2023.
  • A 5-year average of $1.5 billion and a median of $1.4 billion in 2022 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: dropped 18.75% in 2023 and later soared 39.7% in 2025.
  • Year by year, Total Liabilities stood at $1.4 billion in 2022, then fell by 18.75% to $1.1 billion in 2023, then grew by 16.53% to $1.3 billion in 2024, then soared by 39.7% to $1.8 billion in 2025, then rose by 20.91% to $2.2 billion in 2026.
  • Business Quant data shows Total Liabilities for RDY at $2.2 billion in Q1 2026, $1.8 billion in Q1 2025, and $1.3 billion in Q1 2024.